

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 35399

Title: Survival analysis based on HER2 status in stage II-III gastric cancer.

Reviewer's code: 00052339

Reviewer's country: Japan

Science editor: Ze-Mao Gong

Date sent for review: 2017-07-13

Date reviewed: 2017-07-26

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Survival analysis based on HER2 status in stage II-III gastric cancer. Jang Ho Cho, et al This manuscript is very unique because of analyzing stage II-III gastric cancer depending on HER2 overexpression or not, however, I need the elucidation of the following points. #1 From Fig.2, OS was more dependent on HER2 overexpression in Stage III, but not in Stage II (Fig.2A). Thus, the analysis can be done according to stage II or III. #2 Fig.3 can be corrected to each OS in stage II and III who received adjuvant chemotherapy. #3 I would like to know prognostic factor specifically such as HER2 overexpression and adjuvant chemotherapy in stage II or III. Hence, the following analysis should be addressed; OS in Stage II or III who did not receive adjuvant chemotherapy. OS in stage II or III who received adjuvant chemotherapy. RFS in Stage II or III who did not receive adjuvant chemotherapy. RFS in stage II or III who received adjuvant chemotherapy. #4 Table 1 should include the information about the number of patients who received adjuvant chemotherapy. #5 Table 3 did not show how many

factors were included for univariate and multivariate analysis. I think the adjuvant chemotherapy is one factor for the analysis. #6 Compared Fig.3 and Fig.4, OS in patients without overexpression of HER2 is longer in patients who did not receive the adjuvant chemotherapy than those received with adjuvant chemotherapy. What is the reason for this? Is selection bias such as that the patients who did not receive adjuvant chemotherapy were likely in Stage II? #7 In addition, is the adjuvant chemotherapy effective for the patients with HER2 overexpressed gastric cancer?

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 35399

Title: Survival analysis based on HER2 status in stage II-III gastric cancer.

Reviewer's code: 02682861

Reviewer's country: United States

Science editor: Ze-Mao Gong

Date sent for review: 2017-07-24

Date reviewed: 2017-08-01

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input checked="" type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Clear and quite accurate work . The statistics were performed on a fair number of patients. Conclusions agree with those of other works in the literature. Gastric cancer is not the second leading cause of cancer-related deaths in the world, but the third as shows the latest work of Ferlay J et al. of 2015, which you mentioned in the paper before. In Patients Characteristics and in Discussion the number of 834 patients is reported instead of 384.

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 35399

Title: Survival analysis based on HER2 status in stage II-III gastric cancer.

Reviewer's code: 01003401

Reviewer's country: Reviewer_Country

Science editor: Ze-Mao Gong

Date sent for review: 2017-07-24

Date reviewed: 2017-08-08

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Manuscript entitled " Survival analysis based on HER2 status in stage II-III gastric cancer." mainly discussed HER2-positive patients had inferior OS and RFS. Stage II-III HER2-positive patients might be potential candidates for targeted therapies involving trastuzumab. The draft aimed to investigate human epidermal growth factor 2 (HER2) overexpression and validate its prognostic effect in stage II-III gastric cancer. Clinical data from 384 patients were analyzed. HER2-positive patients had inferior OS and RFS. Stage II-III HER2-positive patients might be potential candidates for targeted therapies involving trastuzumab. The data suggested that trastuzumab or other humanized monoclonal antibodies might play a similar role in an adjuvant setting in patients with stage II-III HER2-positive gastric cancer. And further studies are needed. And stage II-III patients exhibiting HER-2/neu amplification might be potential candidates for new adjuvant therapies involving the use of humanized monoclonal antibodies. There is a small question to discuss with the authors as follows. In general, some experimental

study had better to be cited to support the authors` hypothesis, for example the literature like Biomaterials, 2012, 33:5349.